Promoting Adherence in Early-Stage HR+/HER2- Breast Cancer: The Value of Oncology Pharmacists in Preventing Premature Treatment Discontinuation



April 25, 2023 • 1:00pm CT • Virtual Register Here

PTCE invites you to a Live Free Accredited Presentation

EDUCATIONAL OBJECTIVES

After completion of this activity, participants will be able to:

- Explore guideline recommendations for the adjuvant treatment of early-stage HR+/HER2- breast cancer with CDK4/6 inhibitors
- Explain barriers to medication adherence in patients with early-stage HR+/HER2- breast cancer
- Construct pharmacist-driven strategies to help patients overcome barriers to medication adherence in early-stage HR+/HER2- breast cancer
- Apply best practices in patient counseling to individual patient-pharmacist encounters to optimize results of systemic therapy in early-stage HR+/HER2-breast cancer

ACCREDITATION STATEMENT

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-23-132-L01-P. The activity is available for CE credit through June 25, 2023.

FACULTY



Jordan Hill, PharmD, BCOP Oncology Pharmacy Specialist West Virginia University Cancer Institute Morgantown, West Virginia

Jordan Hill, PharmD, BCOP is an Oncology Clinical Pharmacy Specialist at the West Virginia University Cancer Institute in Morgantown, WV. She has worked in the ambulatory breast cancer clinics since transitioning to ambulatory oncology in 2017. Jordan completed her PGY-1 pharmacy practice residency at VA Pittsburgh Healthcare System in 2014 and her PGY-2 oncology pharmacy residency at The Ohio State University in 2015. At WVU, Jordan is a member of the hematology / oncology pharmacy and therapeutics committee, protocol review and monitoring committee, and the data safety and toxicity committee. She is an adjunct faculty member at the WVU School of Pharmacy where she coordinates the oncology elective and teaches the breast cancer component of the therapeutics course. She is the PGY2-Oncology Residency program coordinator and is a primary preceptor for both the PGY-1 and PGY-2 Oncology residency programs.

This activity is supported by an educational grant from Lilly.

